136 completed, 34 unknown, 30 active not recruiting, 30 recruiting. 137 Phase 2, 81 Phase 3, 37 Phase 1, 12 Phase 4, 11 Not applicable.
Follow exemestane: new trials by email Literature Review of exemestane trials Research Report on exemestane
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Neu Direction: Testing the Efficacy of Adding HER Inhibition to Standard of Care in Metastatic MLH1-low Endocrine-resistant ER+/HER2- Breast Cancer Neratinib + endocrine therapy, Endocrine therapy may include one of the following therapies: letrozole, anastrozole, exemestane, tamoxifen or fulvestrant, CDK4/6 + Endocrine therapy - Metastatic Invasive Breast Cancer, Resistant Breast Cancer | Phase 2 | Not yet recruiting | University of California, San Diego | 150 | 2027-07-01 | 2026-07-27 |
| E.N.D.E.A.V.O.R.: An Exemestane Needed Dose Efficacy and Verification as an Ovulation Induction Regimen Study Exemestane 25 MG, Placebo, Exemestane 50 MG - Poly Cystic Ovary Syndrome | Phase 1 | Recruiting | University of North Carolina, Chapel Hill | 40 | 2026-10-01 | 2026-09-23 |
| QL1706 Plus Neoadjuvant Endocrine Therapy in HR-Positive/HER2-Negative Breast Cancer With a Poor Response to Neoadjuvant Chemotherapy Iparomlimab and Tuvonralimab (QL1706), Aromatase Inhibitor (AI), CDK4/6 inhibitor - Breast Cancer | Phase 2 | Not yet recruiting | Hebei Medical University Fourth Hospital | 40 | 2026-10-01 | 2026-08-26 |
| Randomized Double-Blind Phase II Trial of Baby Exemestane Versus Baby Tamoxifen in Post-Menopausal Women at High Risk for Breast Cancer Exemestane, Tamoxifen - Breast Cancer, Ductal Carcinoma | Phase 2 | Not yet recruiting | Dana-Farber Cancer Institute | 140 | 2026-09-09 | 2026-03-30 |
| BRE-06: Study to Increase Tolerance to Aromatase Inhibitors for Patients With Early-Stage Hormone Receptor Positive Breast Cancer Who Developed Hypoactive Sexual Desire Disorder Aromatase Inhibitors, Bupropion, GnRH agonist - Early-stage Breast Cancer, Hypoactive Sexual Desire Disorder | Phase 1 / Phase 2 | Not yet recruiting | University of Illinois at Chicago | 100 | 2026-09-01 | 2026-08-24 |
| Testing Whether Hormone Therapy With Ribociclib is as Effective as Chemotherapy Followed by Hormone Therapy With Ribociclib for the Treatment of High Anatomic Stage Breast Cancer With Low Recurrence Risk, The RxFINE-Low Trial Anastrozole, Biospecimen Collection, Bone Scan - Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8 | Phase 3 | Recruiting | National Cancer Institute (NCI) | 1978 | 2026-08-10 | 2026-10-30 |
| Elacestrant and Exemestane for Patients With Pretreated HR+/HER2- Metastatic Breast Cancer and [18F] FES-avid Lesions (COMBINE) elacestrant and exemestane - Breast Cancer | Phase 2 | Recruiting | European Institute of Oncology | 26 | 2026-05-11 | 2026-05-14 |
| A Phase III Trial Comparing HRS-8080 With Standard Endocrine Therapy in Patients With Intermediate or High Risk Early Breast Cancer HRS-8080 Tablets, Letrozole tablets, Tamoxifen Citrate Tablets - Breast Cancer | Phase 3 | Recruiting | Shandong Suncadia Medicine Co., Ltd. | 5500 | 2026-03-04 | 2026-05-22 |
| Efficacy and Safety of Dalpiciclib Combined With Endocrine Adjuvant Therapy for Early HR +/HER2- Breast Cancer: a Multicenter, Prospective Clinical Study Dalpiciclib 125mg, Dalpiciclib 100mg, Endocrine Therapy (ET): letrozole, anastrozole, exemestane, tamoxifen - Breast Diseases, Breast Neoplasms | Phase 2 | Recruiting | Fujian Cancer Hospital | 2000 | 2026-01-21 | 2026-05-12 |
| A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA) LY4064809, Placebo, Ribociclib - Breast Neoplasms, Neoplasm Metastasis | Phase 3 | Recruiting | Eli Lilly and Company | 800 | 2025-12-22 | 2026-10-08 |
| An Exploratory Study of Pertuzumab and Trastuzumab in Combination With Palbociclib and Exemestane as Neoadjuvant Therapy for Triple-Positive Breast Cancer Trastuzumab and Pertuzumab Combination with Palbociclib and Exemestane - Breast Cancer | Phase 2 | Not yet recruiting | Anhui Provincial Cancer Hospital | 90 | 2025-12-20 | 2025-12-23 |
| Sapu003 in Advanced mTOR-sensitive Solid Tumors Sapu003, Exemestane 25 MG - Breast Cancer Metastatic, Renal Cell Carcinoma (RCC) | Phase 1 | Recruiting | SAPU NANO (US) LLC | 27 | 2025-12-15 | 2026-01-27 |
| Low Dose Exemestane vs Low Dose Tamoxifen in Post-menopausal Women at High Risk for Breast Cancer. Tamoxifen 10 MG, Exemestane 25 MG - Breast Cancer | Phase 2 | Recruiting | Andrea DeCensi | 140 | 2025-10-01 | 2025-11-18 |
| A Trial to Evaluate Sacituzumab Govitecan in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Metastatic Breast Cancer Progressed on CDK4/6 Inhibitors Sacituzumab Govitecan + Fulvestrant, Sacituzumab Govitecan + Anastrozole / Exemestane - Stage IV (Metastatic) Breast Cancer | Phase 1 | Not yet recruiting | Hunan Cancer Hospital | 12 | 2025-10-01 | 2025-09-16 |
| Maintenance Therapy in HER2-Positive Unresectable Locally Recurrent or Metastatic Breast Cancer: A Phase II Study Trastuzumab rezetecan, Pyrotinib, Dalpiciclib - HER2-positive Breast Cancer | Phase 2 | Not yet recruiting | Fudan University | 288 | 2025-09-10 | 2025-09-18 |
| Dalpiciclib as Adjuvant Therapy for HR-positive/HER2-negative Early-stage Patients Dalpiciclib, Endocrine Therapy (Tamoxifen, Anastrozol, Letrozole, Exemestane) - Early Breast Cancer, Adjuvant Therapy | Phase 2 | Not yet recruiting | Fujian Cancer Hospital | 200 | 2025-09-01 | 2025-08-03 |
| A Study of MK-5684 in People With Certain Solid Tumors (MK-5684-015/OMAHA-015) Opevesostat, Fludrocortisone/ Fludrocortisone acetate, Dexamethasone/Dexamethasone acetate - Malignant Neoplasm | Phase 2 | Recruiting | Merck Sharp & Dohme LLC | 250 | 2025-08-11 | 2026-10-06 |
| A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment. PF-07248144, Fulvestrant, Everolimus - Breast Cancer | Phase 3 | Recruiting | Pfizer | 400 | 2025-08-05 | 2026-10-19 |
| A Phase 3 Study of HRS-8080 Versus Treatment Chosen by Physicians in Locally Advanced and Metastatic Breast Cancer HRS-8080 Tablet, Fulvestrant injection, Exemestane tablets - Locally Advanced Breast Cancer, Metastatic Breast Cancer | Phase 3 | Recruiting | Shandong Suncadia Medicine Co., Ltd. | 240 | 2025-07-23 | 2026-10-02 |
| Comparing Endocrine Therapy Combined With High-Dose Palbociclib and Hydroxychloroquine to Endocrine Therapy Combined With Standard-Dose Palbociclib for Hormone Receptor-Positive and HER2-Negative Advanced Breast Cancer Palbociclib 125mg qd (3 weeks of treatment followed by 1 week off) + Anastrozole 1mg qd / Letrozole 2.5mg qd / Exemestane 25mg qd, Palbociclib 125mg qd (3 weeks of treatment followed by 1 week off) + Anastrozole 1mg qd / Letrozole 2.5mg qd / Exemestane 25mg qd + Hydroxychloroquine 600mg bid, Palbociclib 200mg qd (3 weeks of treatment followed by 1 week off) + Anastrozole 1mg qd / Letrozole 2.5mg qd / Exemestane 25mg qd + Hydroxychloroquine 600mg bid - Hormone Receptor-Positive and HER2-Negative Advanced Breast Cancer | Phase 3 | Not yet recruiting | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | 474 | 2025-07-01 | 2025-07-11 |
Showing 20 of 283. Sign in to see all of them.
Breast Neoplasms (230) · Neoplasm Metastasis (19) · Neoplasms (9) · Breast Diseases (7) · Breast Neoplasms, Male (7) · Carcinoma, Intraductal, Noninfiltrating (5) · Ovarian Neoplasms (4) · Breast Carcinoma In Situ (3) · Carcinoma, Non-Small-Cell Lung (3) · Endometrial Neoplasms (3) · Obesity (3) · Recurrence (3) · Arthralgia (2) · Bulbo-Spinal Atrophy, X-Linked (2) · Carcinoma, Renal Cell (2)
Pfizer (28) · Novartis Pharmaceuticals (13) · National Cancer Institute (NCI) (8) · Eli Lilly and Company (7) · AstraZeneca (6) · Dana-Farber Cancer Institute (5) · ETOP IBCSG Partners Foundation (4) · Fudan University (4) · Institut Claudius Regaud (4) · Merck Sharp & Dohme LLC (4) · University of Washington (4) · Boehringer Ingelheim (3) · Chinese Academy of Medical Sciences (3) · GBG Forschungs GmbH (3) · Mayo Clinic (3)
United States (140) · China (48) · France (44) · Spain (42) · United Kingdom (42) · Canada (39) · Italy (39) · Belgium (36) · Germany (34) · South Korea (27) · Australia (26) · Brazil (24) · Argentina (23) · Japan (22) · Hungary (20)
Hannah Linden (4) · Dennis N Morrison, D.O. (3) · Paul E. Goss, MD, PhD (3) · Sabino De Placido, MD (3) · Erica Mayer, MD, MPH (2)
PMID 21247627, PMID 24091623, PMID 24881463, PMID 29885375, PMID 35100692, PMID 41642493, PMID 41980703, PMID 23902874, PMID 25495490, PMID 26092816, PMID 27044936, PMID 28732650, PMID 28911092, PMID 29863451, PMID 31618131, PMID 33451345, PMID 36521078, PMID 36791166, PMID 40017004, PMID 40633461, PMID 40986647, PMID 41637791, PMID 10076721, PMID 11972444, PMID 12490681, PMID 12804433, PMID 12954578, PMID 14760111, PMID 15014181, PMID 15632378, PMID 15894097, PMID 16096437, PMID 16361630, PMID 16959170, PMID 17047401, PMID 17267326, PMID 17301689, PMID 17307102, PMID 17538978, PMID 18024866, PMID 18258986, PMID 18269782, PMID 18332472, PMID 18407954, PMID 18794551, PMID 18809056, PMID 19118028, PMID 19218306, PMID 19364653, PMID 19531217
2014 (5), 2016 (5), 2023 (5), 2004 (3), 2017 (3), U10CA180820 (3), 2005 (2), 2008 (2), 2009 (2), 2018 (2), 2025 (2), P30CA015704 (2), U10CA021115 (2), U10CA032102 (2), U10CA180868 (2)